A New Approach to a Personalized Patient Blood Management Program (pPBM) in Total Hip Arthroplasty (THA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02519088|
Recruitment Status : Completed
First Posted : August 10, 2015
Last Update Posted : October 12, 2015
The study evaluates the patient related risk and predictive factors concerning perioperative homologous blood cell transfusion (erythrocyte concentrate ) in THA patients in one EndoCert max-certified orthopedic hospital in Germany.
A patient oriented preoperative decision-making algorithm (a personalised Patient Blood Management or pPBM App) will be developed as a new patient-safety blood-sparing strategy.
The aim is to increase the patient safety by using the pPBM App and to reach a more efficient management of resources.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||477 participants|
|Official Title:||A New Approach to a Personalized Patient Blood Management Program in Total Hip Arthroplasty|
|Study Start Date :||August 2015|
|Actual Primary Completion Date :||October 2015|
|Actual Study Completion Date :||October 2015|
- Events and circumstances of Homologous Blood Transfusion (erythrocyte concentrate transfusion) [ Time Frame: participants will be followed for the duration of hospital stay, an expected average of 10 days ]Multivariate analysis of predictive variables like age, sex, BMI, hip and belly circumference, chronic kidney disease, chronic cardio-vascular disease, chronic inflammatory disease, diabetes mellitus, cancer, ASA Score, cemented, hybrid or not cemented prosthesis, surgery duration, medication and hemoglobin level before surgery
- pPBM Computer Simulation [ Time Frame: participants will be followed for the duration of hospital stay, an expected average of 10 days ]Introducing the pPBM App as a safe blood-sparing strategy
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02519088
|Krankenhaus der Barmherzigen Brüder Trier|
|Trier, Rheinland-Pfalz, Germany, 54292|
|Principal Investigator:||Ion-Andrei Popescu, MD||Krankenhaus der Barmherzigen Brüder Trier|